Evidence map›Paper›PMID 37968320›Full record

ArticleScientific reports2023

Prediction of alternative pre-mRNA splicing outcomes.

Rayan Najjar, Tomas Mustelin

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rayan NajjarDivision of Rheumatology, Department of Medicine, University of Washington, 750 Republican Street, Seattle, WA, 98109, USA. najjar@uw.edu.
Tomas MustelinDivision of Rheumatology, Department of Medicine, University of Washington, 750 Republican Street, Seattle, WA, 98109, USA.
University of Washington · US

Funding

RESEARCH TRAINING IN RHEUMATOLOGYT32AR007108 · NIAMS · UNIVERSITY OF WASHINGTON · PI Shaun Jackson, Tomas M Mustelin · 1986 to 2026
$6.6M
Upstream drivers of type I interferons in lupusR01AI186337 · NIAID · UNIVERSITY OF WASHINGTON · PI Joanne Michelle Kahlenberg, John LaCava · 2024 to 2026
$2.3M
Role of the L1 retrotransposon in interferon-positive SLER01AR081654 · NIAMS · UNIVERSITY OF WASHINGTON · PI Tomas M Mustelin · 2023 to 2026
$2.1M
Role of protein citrullination in rheumatoid arthritisR01AR074939 · NIAMS · UNIVERSITY OF WASHINGTON · PI MUSTELIN, TOMAS M · 2020 to 2024
$1.9M
Regulation of the tumor suppressor PTENR01CA096949 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MUSTELIN, TOMAS M · 2003 to 2006
$1.4M
Alternative splicing and expression of transposable elements in aging skeletal muscleR21AG087517 · NIA · UNIVERSITY OF WASHINGTON · PI MUSTELIN, TOMAS M · 2024 to 2024
$485k
Altered protein structures and neoepitopes in lupus neutrophils from dysregulated splicing of messenger RNAR21AI183320 · NIAID · UNIVERSITY OF WASHINGTON · PI Tomas M Mustelin · 2025 to 2026
$477k
The roots of SLE: Can we cure it with a reverse transcriptase inhibitor?R21AR075134 · NIAMS · UNIVERSITY OF WASHINGTON · PI MUSTELIN, TOMAS M · 2019 to 2020
$427k
HERV-K immunity, a trigger of citrullination in rheumatoid arthritis?R21AR077266 · NIAMS · UNIVERSITY OF WASHINGTON · PI MUSTELIN, TOMAS M · 2021 to 2022
$425k
NCI NIH HHS R01 CA096949NIAID NIH HHS R01 AI186337NIAID NIH HHS R21 AI183320NIAMS NIH HHS R01 AR074939NIAMS NIH HHS R01 AR081654NIAMS NIH HHS R21 AR075134NIAMS NIH HHS R21 AR077266NIAMS NIH HHS T32 AR007108NIA NIH HHS R21 AG087517
6 · The paper itself

Abstract

To understand the biological impact of alternative pre-mRNA splicing, it is vital to know which exons are involved, what protein domains they encode, and how the translated isoforms differ. Therefore, we developed a computational pipeline (RiboSplitter) focused on functional effect prediction. It builds on event-based alternative splicing detection with additional filtering steps leading to more efficient statistical testing, and with detection of isoform-specific protein changes. A key methodological advance is reading frame prediction by translating exonic DNA in all possible frames, then finding a single open reading frame, or a single frame with matches to known proteins of the gene. This allowed unambiguous translation in 93.9% of alternative splicing events when tested on RNA-sequencing data of B cells from Sjögren's syndrome patients. RiboSplitter does not depend on reference annotations and translates events even when one or both isoform(s) are novel (unannotated). RiboSplitter's visualizations illustrate each event with translation outcomes, show event location within the gene, and align exons to protein domains.

Indexed as

RNA PrecursorsRNA SplicingAlternative SplicingHumansProtein IsoformsRNA, MessengerProtein IsoformsRNA, MessengerRNA Precursors

Identifiers

PMID37968320
PMCPMC10651857
OpenAlexW4388694195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.